Probing the architecture of the Mycobacterium marinum arylamine N-acetyltransferase active site

Abstract

Treatment of latent tuberculosis infection remains an important goal of global TB eradication. To this end, targets that are essential for intracellular survival of Mycobacterium tuberculosis are particularly attractive. Arylamine N-acetyltransferase (NAT) represents such a target as it is, along with the enzymes encoded by the associated gene cluster, essential for mycobacterial survival inside macrophages and involved in cholesterol degradation. Cholesterol is likely to be the fuel for M. tuberculosis inside macrophages. Deleting the nat gene and inhibiting the NAT enzyme prevents survival of the microorganism in macrophages and induces cell wall alterations, rendering the mycobacterium sensitive to antibiotics to which it is normally resistant. To date, NAT from M. marinum (MMNAT) is considered the best available model for NAT from M. tuberculosis (TBNAT). The enzyme catalyses the acetylation and propionylation of arylamines and hydrazines. Hydralazine is a good acetyl and propionyl acceptor for both MMNAT and TBNAT. The MMNAT structure has been solved to 2.1 ? resolution following crystallisation in the presence of hydralazine and is compared to available NAT structures. From the mode of ligand binding, features of the binding pocket can be identified, which point to a novel mechanism for the acetylation reaction that results in a 3-methyltriazolo[3,4-a]phthalazine ring compound as product.

Key words： Mycobacterium tuberculosis; Mycobacterium marinum; tuberculosis; arylamine N-acetyltransferase; 3D crystal structure; binding pocket

References

[1] Anderton, M.C., Bhakta, S., Besra, G.S., Jeavons, P., Eltis, L.D., and Sim, E. (2006). Characterization of the putative operon containing arylamine N-acetyltransferase (nat) in Mycobacterium bovis BCG. Mol Microbiol 59, 181-192 .10.1111/j.1365-2958.2005.04945.x
[2] Bhakta, S., Besra, G.S., Upton, A.M., Parish, T., Sholto-Douglas-Vernon, C., Gibson, K.J., Knutton, S., Gordon, S., DaSilva, R.P., Anderton, M.C., . (2004). Arylamine N-acetyltransferase is required for synthesis of mycolic acids and complex lipids in Mycobacterium bovis BCG and represents a novel drug target. J Exp Med 199, 1191-1199 .10.1084/jem.20031956
[3] Binkowski, T.A., Naghibzadeh, S., and Liang, J. (2003). CASTp: Computed atlas of surface topography of proteins. Nucleic Acids Res 31, 3352-3355 .10.1093/nar/gkg512
[4] Brown, A.K., Taylor, R.C., Bhatt, A., Fütterer, K., Besra, G.S., and Ahmed, N. (2009). Platensimycin activity against mycobacterial β-ketoacyl-ACP synthases. PLoS ONE 4 , e6306.10.1371/journal.pone.0006306
[5] Butler, A.R., and Gold, V. (1961). The hydrolysis of acetic anhydride. Part VII. Catalysis by pyridine and methylpyridines in acetate buffers. J Chem Soc , 4362-4367 .10.1039/jr9610004362
[6] Chaudhry, C., Horwich, A.L., Brunger, A.T., and Adams, P.D. (2004). Exploring the structural dynamics of the E.coli chaperonin GroEL using translation-libration-screw crystallographic refinement of intermediate states. J Mol Biol 342, 229-245 .10.1016/j.jmb.2004.07.015
[7] Collaborative (1994). The CCP4 suite: programs for protein crystallography. Acta Crystallogr Sect D Biol Crystallogr 50, 760-763 .
[8] Datta, V.N., Brien, R.D., Kathleen, M.M., and Stephen, G.S. (1976). Fluorescence of hydralazine in concentrated sulfuric acid. J Pharm Sci 65, 274-276 .10.1002/jps.2600650223
[9] Dooley, K.E., and Sterling, T.R. (2005). Treatment of latent tuberculosis infection: challenges and prospects. Clin Chest Med 26, 313-326, vii .10.1016/j.ccm.2005.02.003
[10] Emsley, P., and Cowtan, K. (2004). Coot: model-building tools for molecular graphics. Acta Crystallogr D Biol Crystallogr 60, 2126-2132 .10.1107/S0907444904019158
[11] Evans, P. (2006). Scaling and assessment of data quality. Acta Crystallogr D Biol Crystallogr 62, 72-82 .10.1107/S0907444905036693
[12] Flynn, J.L., and Chan, J. (2003). Immune evasion by Mycobacterium tuberculosis: living with the enemy. Curr Opin Immunol 15, 450-455 .10.1016/S0952-7915(03)00075-X
[13] Fullam, E. (2007). Arylamine N-acetyltransferase of Mycobacterium marinum. D. Phil. Thesis, University of Oxford, UK .
[14] Fullam, E., Westwood, I.M., Anderton, M.C., Lowe, E.D., Sim, E., and Noble, M.E. (2008). Divergence of cofactor recognition across evolution: coenzyme A binding in a prokaryotic arylamine N-acetyltransferase. J Mol Biol 375, 178-191 .10.1016/j.jmb.2007.10.019
[15] Fullam, E., Kawamura, A., Wilkinson, H., Abuhammad, A., Westwood, I., and Sim, E. (2009). Comparison of the Arylamine N-acetyltransferase from Mycobacterium marinum and Mycobacterium tuberculosis. Protein J 28, 281-293 .10.1007/s10930-009-9193-0
[16] Gallivan, J.P., and Dougherty, D.A. (1999). Cation-π interactions in structural biology. Proc Natl Acad Sci U S A 96, 9459-9464 .10.1073/pnas.96.17.9459
[17] Gumbo, T., Dona, C.S., Meek, C., and Leff, R. (2009). Pharmacokinetics-pharmacodynamics of pyrazinamide in a novel in vitro model of tuberculosis for sterilizing effect: a paradigm for faster assessment of new antituberculosis drugs. Antimicrob Agents Chemother 53, 3197-3204 .10.1128/AAC.01681-08
[18] Hendlich, M. (1998). Databases for protein-ligand complexes. Acta Crystallogr D Biol Crystallogr 54, 1178-1182 .10.1107/S0907444998007124
[19] Lack, N.A., Kawamura, A., Fullam, E., Laurieri, N., Beard, S., Russell, A.J., Evangelopoulos, D., Westwood, I., and Sim, E. (2009). Temperature stability of proteins essential for the intracellular survival of Mycobacterium tuberculosis. Biochem J 418, 369-378 .10.1042/BJ20082011
[20] Leslie, A.G. (2006). The integration of macromolecular diffraction data. Acta Crystallogr D Biol Crystallogr 62, 48-57 .10.1107/S0907444905039107
[21] Makarov, V., Manina, G., Mikusova, K., Mollmann, U., Ryabova, O., Saint-Joanis, B., Dhar, N., Pasca, M.R., Buroni, S., Lucarelli, A.P., . (2009). Benzothiazinones kill Mycobacterium tuberculosis by blocking arabinan synthesis. Science 324, 801-804 .10.1126/science.1171583
[22] Manabe, Y.C., and Bishai, W.R. (2000). Latent Mycobacterium tuberculosis-persistence, patience, and winning by waiting. Nat Med 6, 1327-1329 .10.1038/82139
[23] Matthews, B.W. (1968). Solvent content of protein crystals. J Mol Biol 33, 491-497 .10.1016/0022-2836(68)90205-2
[24] McShane, H. (2005). Co-infection with HIV and TB: double trouble. Int J STD AIDS 16, 95-101 .10.1258/0956462053057576
[25] Meot-Ner, M., and Deakyne, C.A. (1985). Unconventional ionic hydrogen bonds. 2. NH+.cntdot.cntdot.cntdot.pi. Complexes of onium ions with olefins and benzene derivatives. J Am Chem Soc 107, 474-479 .10.1021/ja00288a034
[26] Murshudov, G.N., Vagin, A.A., and Dodson, E.J. (1997). Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr D Biol Crystallogr 53, 240-255 .10.1107/S0907444996012255
[27] Okabe, N., Fukuda, H., and Nakamura, T. (1993). Structure of hydralazine hydrochloride. Acta Crystallogr. Sect C: Cryst Struct Commun 49, 1844-1845 .10.1107/S0108270193003762
[28] Pandey, A.K., and Sassetti, C.M. (2008). Mycobacterial persistence requires the utilization of host cholesterol. Proc Natl Acad Sci U S A 105, 4376-4380 .10.1073/pnas.0711159105
[29] Potterton, L., McNicholas, S., Krissinel, E., Gruber, J., Cowtan, K., Emsley, P., Murshudov, G.N., Cohen, S., Perrakis, A., and Noble, M. (2004). Developments in the CCP4 molecular-graphics project. Acta Crystallogr D Biol Crystallogr 60, 2288-2294 .10.1107/S0907444904023716
[30] Rengarajan, J., Bloom, B.R., and Rubin, E.J. (2005). Genome-wide requirements for Mycobacterium tuberculosis adaptation and survival in macrophages. Proc Natl Acad Sci U S A 102, 8327-8332 .10.1073/pnas.0503272102
[31] Rivers, E.C., and Mancera, R.L. (2008). New anti-tuberculosis drugs in clinical trials with novel mechanisms of action. Drug Discov Today 13, 1090-1098 .10.1016/j.drudis.2008.09.004
[32] Rodham, D.A., Suzuki, S., Suenram, R.D., Lovas, F.J., Dasgupta, S., Goddard, W.A. III, and Blake, G.A. (1993). Hydrogen bonding in the benzene-ammonia dimer. Nature 362, 735-737 .10.1038/362735a0
[33] Sandy, J., Holton, S., Fullam, E., Sim, E., and Noble, M. (2005a). Binding of the anti-tubercular drug isoniazid to the arylamine N-acetyltransferase protein from Mycobacterium smegmatis. Protein Sci 14, 775-782 .10.1110/ps.041163505
[34] Sandy, J., Mushtaq, A., Holton, S.J., Schartau, P., Noble, M.E., and Sim, E. (2005b). Investigation of the catalytic triad of arylamine N-acetyltransferases: essential residues required for acetyl transfer to arylamines. Biochem J 390, 115-123 .10.1042/BJ20050277
[35] Sikora, A.L., Frankel, B.A., and Blanchard, J.S. (2008). Kinetic and chemical mechanism of arylamine N-acetyltransferase from Mycobacterium tuberculosis. Biochemistry 47, 10781-10789 .10.1021/bi800398c
[36] Sim, E., Sandy, J., Evangelopoulos, D., Fullam, E., Bhakta, S., Westwood, I., Krylova, A., Lack, N., and Noble, M. (2008). Arylamine N-acetyltransferases in mycobacteria. Curr Drug Metab 9, 510-519 .10.2174/138920008784892100
[37] Sinclair, J.C., Sandy, J., Delgoda, R., Sim, E., and Noble, M.E.M. (2000). Structure of arylamine N-acetyltransferase reveals a catalytic triad. Nat Struct Biol 7, 560-564 .10.1038/76783
[38] Smith, I. (2003). Mycobacterium tuberculosis pathogenesis and molecular determinants of virulence. Clin Microbiol Rev 16, 463-496 .10.1128/CMR.16.3.463-496.2003
[39] Vagin, A., and Teplyakov, A. (2000). An approach to multi-copy search in molecular replacement. Acta Crystallogr D Biol Crystallogr 56, 1622-1624 .10.1107/S0907444900013780
[40] Westwood, I. (2005). Structure and activity of Arylamine N-acetyltransferase form Pseudomonas aeruginosa. D. Phil. Thesis, University of Oxford, UK .
[41] Westwood, I.M., Kawamura, A., Fullam, E., Russell, A.J., Davies, S.G., and Sim, E. (2006). Structure and mechanism of arylamine N-acetyltransferases. Curr Top Med Chem 6, 1641-1654 .10.2174/156802606778108979
[42] Westwood, I., Bhakat, S., Russell, A., Fullam, E., Anderton, M., Kawamura, A., Mulvaney, A., Vickers, R., Bhowruth, V., Besra, G., . (2010). Identification of aryalmine N-acetyltransferase inhibitors as an approach towards novel anti-tuberculars. Protein Cell 1, 82-95 .10.1007/s13238-010-0006-1
[43] WHO. (2009). Global tuberculosis control report- epidemiology, strategy, financing (http://www.who.int/tb/publications/global_report/2009/).
[44] Winn, M.D., Isupov, M.N., and Murshudov, G.N. (2001). Use of TLS parameters to model anisotropic displacements in macromolecular refinement. Acta Crystallogr D Biol Crystallogr 57, 122-133 .10.1107/S0907444900014736
[45] Wouters, J. (1998). Cation-pi (Na+-Trp) interactions in the crystal structure of tetragonal lysozyme. Protein Sci 7, 2472-2475 .10.1002/pro.5560071127
[46] Yam, K.C., D’Angelo, I., Kalscheuer, R., Zhu, H., Wang, J.-X., Snieckus, V., Ly, L.H., Converse, P.J., Jacobs, W.R. Jr, Strynadka, N., . (2009). Studies of a ring-cleaving dioxygenase illuminate the role of cholesterol metabolism in the pathogenesis of Mycobacterium tuberculosis. PLoS Pathog 5, e1000344.10.1371/journal.ppat.1000344